Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2014 Aug 17;33(1):63.
doi: 10.1186/s13046-014-0063-z.

Perioperative changes in pro and anticoagulant factors in prostate cancer patients undergoing laparoscopic and robotic radical prostatectomy with different anaesthetic techniques

Maria Sofra  1 , Anna Antenucci  2 , Michele Gallucci  3 , Chiara Mandoj  4 , Rocco Papalia  5 , Claudia Claroni  6 , Ilaria Monteferrante  7 , Giulia Torregiani  8 , Valeria Gianaroli  9 , Isabella Sperduti  10 , Luigi Tomao  11 , Ester Forastiere  12
Affiliations
Randomized Controlled Trial

Perioperative changes in pro and anticoagulant factors in prostate cancer patients undergoing laparoscopic and robotic radical prostatectomy with different anaesthetic techniques

Maria Sofra et al. J Exp Clin Cancer Res. .

Abstract

Background: Laparoscopic prostatectomy (LRP) may activate clotting system influencing the risk of perioperative thrombosis in patients with prostate cancer. Moreover, different anaesthetic techniques can also modify coagulant factors. Thus, the aim of this study was to investigate the effects on pro- and anti-coagulant and fibrinolytic factors of two established types of anaesthesia in patients with prostate cancer undergoing elective LRP.

Methods: 102 patients with primary prostate cancer, who underwent conventional LRP or robot-assisted laparoscopic prostatectomy (RALP), were studied and divided into 2 groups to receive total intravenous anesthesia with target-controlled infusion (TIVA-TCI) or balanced inhalation anaesthesia (BAL) prior to surgery. Before the induction of anaesthesia (T0), 1 hr (T1) and 24 hrs post-surgery (T2), some pro-coagulant factors, fibronolysis markers, p-selectin and haemostatic system inhibitors were evaluated.

Results: Both TIVA-TCI and BAL patients showed a marked and significant increase in pro-coagulant factors and consequent reduction in haemostatic system inhibitors in the early post operative period (p ≤ 0.004 for each markers). Use of RALP showed a significant increase in prothrombotic markers as compared to LRP. In TIVA patients undergoing LRP, a significant reduction of p-selectin levels between T0 and T2 (p = 0.001) was observed as compared to BAL, suggesting a better protective effect on platelet activation of anaesthetic agents used for TIVA.

Conclusions: Both anaesthetic techniques significantly seem to increase the risk of thrombosis in prostate cancer patients undergoing LRP, mainly when the robotic device was utilized, encouraging the use of a peri-operative thromboembolic prophylaxis in these patients.

Trial registration: ClinicalTrials.gov NCT01998685.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Coagulation cascade. The solid lines indicate a activating function, while the dashed lines a inhibitory action.
Figure 2
Figure 2
Design of the study: patient selection.
Figure 3
Figure 3
Changes of p-selectin levels between T0 (before the induction of anaesthesia) and T2 (24 hrs post-surgery) in patients undergoing conventional laparoscopic radical prostatectomy (LRP) or robot-assisted laparoscopic prostatectomy (RALP). TIVA-TCI patients undergoing LRP showed a significant reduction in p-selectin levels between T0 and T2 (p?=?0.001) while no changes were observed in the BAL group. In contrast, a significant increase of p-selectin value was observed 24 hours after surgery (T2) in patients undergoing RALP, regardless of the type of anaesthesia.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Sorensen HT, Mellemkjaer L, Olsen JH, Baron JA. Prognosis of cancers associated with venous thromboembolism. N Engl J Med. 2000;343:1846–50. doi: 10.1056/NEJM200012213432504. - DOI - PubMed
    1. Prandoni P, Falanga A, Piccioli A. Cancer and venous thromboembolism. Lancet Oncol. 2005;6:401–10. doi: 10.1016/S1470-2045(05)70207-2. - DOI - PubMed
    1. Heit JA. Venous thromboembolism: disease burden, outcomes and risk factors. J Thromb Haemost. 2005;3:1611–7. doi: 10.1111/j.1538-7836.2005.01415.x. - DOI - PubMed
    1. Chew HK, Wun T, Harvey D, Zhou H, White RH. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med. 2006;166:458–64. doi: 10.1001/archinte.166.4.458. - DOI - PubMed
    1. ten Cate H, Falanga A. Overview of the postulated mechanisms linking cancer and thrombosis. Pathophysiol Haemost Thromb. 2008;36:122–30. doi: 10.1159/000175150. - DOI - PubMed

Publication types

MeSH terms

Substances

Associated data